Data-driven Value Analysis
Value analysis, anchored in data.
Capital decisions deserve evidence, not intuition. We help sponsors and investors quantify the addressable opportunity, the competitive landscape, and the realistic clinical and commercial positioning of an asset — drawn from primary data, not vendor-style market reports.
Related reading
Why it matters
Capital allocation in biopharma has become more disciplined and more analytical. Investors, BD teams, and portfolio committees increasingly demand evidence-based answers to fundamental questions: how large is the addressable population, what does the competitive landscape look like, and what is the realistic clinical and commercial opportunity?
What we offer
- Indication-level epidemiological modeling
- Pipeline benchmarking against global oncology trials
- Patient population sizing and addressable market analysis
- Competitive landscape analytics
- Korea-specific market access readiness scoring
- Therapeutic area landscape reports
How we work
We build value analyses from primary data sources — KOSIS, NHIS, HIRA, KCCR, ClinicalTrials.gov, EU CTR, and peer-reviewed literature — combined with the sponsor's strategic question. The output is a clear, quantitative basis for decision-making, not a marketing-style report.
Related services
- R&D Planning & Strategy — value analysis feeds development planning